US 9,517,261 B2 · Second generation virus-like particles (VLP) from Epstein-Barr viruses for vaccination purposes

Abstract

The present invention relates to an Epstein-Barr virus-like particle (EB-VLP) substantially free of Epstein-Barr Virus (EBV) DNA. The present invention also relates to a polynucleotide comprising an EBV genome a) lacking at least one expressible gene selected from the group consisting of the BFLF1 gene, the BBRF gene, the BGRF1 gene, the BDRF1 gene, the BALF3 gene, the BFRF1A gene, and the BFRF1 gene, and b) producing the EB-VLP of the invention in a suitable host cell. The present invention further relates to a vector and a host cell comprising the polynucleotide of the invention as well to a method of manufacturing the EB-VLPs, a method of manufacturing a vaccine thereof, a vaccine and a composition comprising the EB-VLPs.

Claims17

Dependent claims

A preparation of Epstein-Barr virus-like particles (EB-VLPs) substantially free of Epstein-Barr Virus (EBV) DNA, wherein said EB-VLPs were generated from EBV lacking at least one functional gene selected from the group consisting of the BFLF1 gene, the BBRF1 gene, the BGRF1 gene, the BDRF1 gene, the BALF3 gene, and the BFRF1A gene;

wherein, in the EB-VLPs substantially free of EBV DNA, the number of EBV DNA-free VLPs produced from said EBV lacking said at least one functional gene is increased as compared to VLPs produced from an EBV mutant strain in which the terminal repeats have been deleted (ΔTR-EBV).

Dependencies are inferred from the claim text.

Second generation virus-like particles (VLP) from Epstein-Barr viruses for vaccination purposes

Life of this patent

Second generation virus-like particles (VLP) from Epstein-Barr viruses for vaccination purposes

Life of this patent

Abstract

Claims17